Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains.
about
The HTLV-1 Tax interactomeAlternative modes of binding of proteins with tandem SH2 domainsThe p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complexFBXL2- and PTPL1-mediated degradation of p110-free p85β regulatory subunit controls the PI(3)K signalling cascadeEmerging common themes in regulation of PIKKs and PI3KsMechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunitThe structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutationsA frequent kinase domain mutation that changes the interaction between PI3K and the membraneStructure of Lipid Kinase p110β/p85β Elucidates an Unusual SH2-Domain-Mediated Inhibitory MechanismRegulation of lipid binding underlies the activation mechanism of class IA PI3-kinasesAutoinhibition and Phosphorylation-Induced Activation of Phospholipase C-γ IsozymesReceptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.The protein-tyrosine phosphatase TCPTP regulates epidermal growth factor receptor-mediated and phosphatidylinositol 3-kinase-dependent signalingMolecular mechanism behind rotavirus NSP1-mediated PI3 kinase activation: interaction between NSP1 and the p85 subunit of PI3 kinaseSignaling by the phosphoinositide 3-kinase family in immune cellsReduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetesv-Crk activates the phosphoinositide 3-kinase/AKT pathway by utilizing focal adhesion kinase and H-Ras.Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS).In brain, Axl recruits Grb2 and the p85 regulatory subunit of PI3 kinase; in vitro mutagenesis defines the requisite binding sites for downstream Akt activation.Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alphaLoss of protein tyrosine phosphatase N2 potentiates epidermal growth factor suppression of intestinal epithelial chloride secretion.Vascular endothelial growth factor receptor 1 contributes to Escherichia coli K1 invasion of human brain microvascular endothelial cells through the phosphatidylinositol 3-kinase/Akt signaling pathway.Autophosphorylation of serine 608 in the p85 regulatory subunit of wild type or cancer-associated mutants of phosphoinositide 3-kinase does not affect its lipid kinase activityOncogenic activity of the regulatory subunit p85β of phosphatidylinositol 3-kinase (PI3K)The structure of the inter-SH2 domain of class IA phosphoinositide 3-kinase determined by site-directed spin labeling EPR and homology modeling.Identification of mutations in distinct regions of p85 alpha in urothelial cancer.Dynamics of the phosphoinositide 3-kinase p110δ interaction with p85α and membranes reveals aspects of regulation distinct from p110αPI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.Regulation of phosphoinositide 3-kinase by its intrinsic serine kinase activity in vivo.Evolutionary history of phosphatidylinositol- 3-kinases: ancestral origin in eukaryotes and complex duplication patterns.The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions.Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).Autophagic pathways as new targets for cancer drug development.Insulin-like growth factor-I stimulates Shc-dependent phosphatidylinositol 3-kinase activation via Grb2-associated p85 in vascular smooth muscle cellsAlteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.Silencing the alarms: Innate immune antagonism by rotavirus NSP1 and VP3Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.Myristoylated p110α Causes Embryonic Death Due to Developmental and Vascular Defects.Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches
P2860
Q21093224-DF6C4719-30B0-41D1-AB1D-EBCF3697A4EBQ22253843-E9FC44FF-83C8-4A27-99E5-B5C552F4BD56Q24310123-56CDFF36-CE99-4601-B559-87F79A02A222Q24338848-2A497457-4FB2-4F55-959A-2449B8E9410EQ24647293-83E70AE7-6D8A-4EB0-8DE3-B785408968AFQ27646654-50567281-6793-48A4-A21B-0309CA67AD97Q27649316-BF79A36F-7C52-4AB5-B1F4-0F2E6E5099F9Q27657679-B7CCEF61-999A-43B2-A55F-BF6A0C9BA08FQ27667112-25D8AFE3-85AD-4E41-8B32-315FDCF781BFQ27675831-B60D9048-6C4A-42EF-9CEA-C73690E62F0BQ27678692-69145EAE-246B-45FC-8B91-59AA073AC7A3Q27851674-1D3769C0-EAD3-4E98-9217-EED262C2805AQ28144437-AEAF5AF0-2599-4B12-81D6-10A10C50CD3FQ28280924-31A4FC23-CC92-4C87-83F1-845F8ADE66ECQ28283677-2F0DC65D-6FD4-466A-9C68-108A9EF02B91Q28344700-EEAE4EA9-1567-4582-8837-C343A9132595Q30165212-395744D5-5F25-4C56-A69C-856705C23AFAQ30538272-35E37676-A9FA-4707-8A4E-3E04ED5BD866Q33999355-2E061789-6092-4573-9490-885E74BF2932Q34100548-A2CDB695-3359-4AEA-84E5-874FBA48B175Q34212116-3FD73FE6-F8E3-41C6-A7CF-0A0D9906979DQ34290785-6B2045E4-F78D-41D2-9370-3A8E7B8E0A3CQ34524060-53C70F57-19AC-479D-B11E-6A39981D9D6CQ34601157-6713ABE6-9B84-4EC6-9026-6A99DBB0C421Q34868530-E2248E4F-F43A-444A-B554-651D2EE48282Q35075756-D0C5FF18-609B-4E3A-8216-11E57B80F36EQ35161212-A486209D-2FE6-4066-88C6-A0FD3E5BF633Q35260766-3A6F84D6-8BCC-4946-A135-1C487EC2EE36Q35544459-76C96C83-EBBB-4E34-8FC5-A1F2E2344F9BQ35813677-0CB8395F-5F26-4AE8-AC8F-41B33D71DBFDQ36150234-B728ECC3-CF73-42EF-A78C-67C7F9636F10Q36279889-212F3B22-77B3-4F61-8425-F81063855F20Q36654185-CE804FCB-1BC3-4B14-B2D4-7F4227F6E3D2Q36711111-C87BD4A6-0F43-4690-B7E3-D7EF42D8011FQ36973814-FF9645DB-DEB4-4100-9C6B-0876AB2CF317Q37083338-A5DE4CF0-BAF1-4FE8-BA01-A3D23D0B015AQ37109227-DC3379ED-538A-401F-881F-5060F5258558Q37138629-623848B6-6A2A-4393-9D6B-ACA7191BF7FBQ37140410-E433E57D-7F25-45BB-873A-622B0D717D15Q37192606-5913B498-99BB-4007-B65B-A24687FB3445
P2860
Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains.
description
1998 nî lūn-bûn
@nan
1998 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Regulation of the p85/p110alph ...... al and c-terminal SH2 domains.
@ast
Regulation of the p85/p110alph ...... al and c-terminal SH2 domains.
@en
type
label
Regulation of the p85/p110alph ...... al and c-terminal SH2 domains.
@ast
Regulation of the p85/p110alph ...... al and c-terminal SH2 domains.
@en
prefLabel
Regulation of the p85/p110alph ...... al and c-terminal SH2 domains.
@ast
Regulation of the p85/p110alph ...... al and c-terminal SH2 domains.
@en
P2093
P2860
P356
P1476
Regulation of the p85/p110alph ...... al and c-terminal SH2 domains.
@en
P2093
P2860
P304
30199-30203
P356
10.1074/JBC.273.46.30199
P407
P577
1998-11-01T00:00:00Z